Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will...

Related Keywords

Dublin ,Ireland ,Switzerland ,France ,Florida ,United States ,Orlando ,United Kingdom ,Israel ,Australia ,Kingswood ,County South Dublin ,Japan ,Great Britain ,French ,American ,Andrean Flynn ,Kelvin Tan ,Kristin Bhavnani ,Nasdaq ,Access Program ,National Institute Of Neurological Disorders ,American Epilepsy Society ,Arts Alliance ,Epilepsy Foundation ,Tuberous Sclerosis Alliance ,European Medicines Agency ,Regulatory Agency ,Drug Administration ,National Organization For Rare Disorders Inc ,Therapeutic Goods Administration ,Jazz Pharmaceuticals ,European Union ,United States Expanded Access Program ,European Commission ,Epilepsy Society ,Expanded Access Program ,Label Extension ,Jazz Pharmaceutical ,World Outcomes ,Treatment Resistant Focal Epilepsies ,Experience From ,Term Effectiveness ,Cannabidiol Against Focal Seizures ,Tuberous Sclerosis Complex ,Results From ,Reported Nonseizure Outcomes ,Real World Use ,Interim Results From ,Reported Seizure Outcomes ,Interim Results ,Acute Mouse Model ,Adult Patients From ,With Open Label Extension ,Anxiolytic Medications ,Against Focal Onset Seizures ,Treatment Resistant Epilepsies ,Adults With Treatment Resistant Epilepsies ,Long Term Results From ,Nutrition Services ,Israel Ministry ,Orphan Drug Designation ,Antiepileptic Drugs ,North American Antiepileptic Drug ,Prescribing Information ,Global Strategic Brand ,Accessed November ,Neurological Disorders ,Tuberous Sclerosis ,Accessed October ,Rare Disorders ,Lennox Gastaut Syndrome ,Jazz Pharmaceuticals Plc ,